Scientists have
pinpointed 15 locations in the human DNA that are linked to depression, one of
the world’s most common mental health conditions and that costs the healthcare
industry billions in medical costs and lost productivity, the Washington Post
reports.
While gene association studies – research that link inherited DNA to
particular diseases, conditions and lifestyle habits – are conducted regularly,
this particular study is important because of its scope. It’s the first
large-scale study on major depressive disorders in people of European lineage,
and shows that the genes that may be associated with depression correspond to
those that help develop neurons in the brain.
The study, conducted by teams
from the Massachusetts General Hospital and the University of Pennsylvania,
also found an overlap between the genetic regions seen in depression and those
that are related to psychiatric disorders like schizophrenia.
These findings
support an earlier study, published in April, that highlighted genetic factors
related to well-being and depression, and found that variants for those
particular genes had a “moderate” overlap with those associated with
schizophrenia and bipolar disorder.
Researchers
studied genetic variations of 75,607 people of European descent who had
reported themselves as suffering from depression, and 231,747 healthy people as
a control group. But while the results are intriguing, they are unlikely to
yield any new treatments soon.
Science has been discovering genes associated
with mental illnesses for the past decades, but have not figured out how to
translate these studies into viable ways to help people.
In addition,
scientists believe that environmental factors play a huge role in depression,
so it’s not something that can be treated easily by gene therapy or similar
treatments. Roy Perlis, associate director of the psychiatric genetics program
in mood and anxiety disorders at Massachusetts General Hospital, says, We hope
these findings help people understand that depression is a brain disease with
its own biology.
He adds that the hard work is now in developing the study into
a treatment. The other significant aspect about this study is that its data
came from people who had sent their saliva to 23andMe, a Silicon Valley company
dealing with personal genomics, and consented to the use of the data for
research. Anne Wojcicki, founder of 23andMe, said that the decision to share
the company’s data and partner with outside researchers is one of the most
important things she had done when she began the company. 23andMe is now one of
the world’s key players in genetics.
Previously, research groups have attempted
to create their own large DNA databases and have run into trouble in getting it
done. It’s possible that the world’s biggest pharmaceutical companies have
genetic data, but they are certainly not going to share it with academic
researchers. By comparison, 23andMe has a whole division working with academic
researchers.
The database is vast, containing over 450,000 customers who have
consented to anonymous research participation, but it’s not perfect, being
based on saliva rather than blood.
Saliva is considered less reliable because
of naturally degrading enzymes and bacteria. 23andMe also looks at certain
points in the genome, and does not conduct a full genome sequence. 23andMe has
published numerous groundbreaking studies on DNA and its influence on human
health, such as genetic susceptibility to migraines or how people are either
morning people or night owls. The study was published in Nature Genetics.
No comments:
Post a Comment